Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) Return on Sales (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Return on Sales for 8 consecutive years, with 67.09% as the latest value for Q4 2025.

  • Quarterly Return on Sales fell 8960.0% to 67.09% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 67.09% through Dec 2025, down 8960.0% year-over-year, with the annual reading at 45.26% for FY2025, 6914.0% down from the prior year.
  • Return on Sales for Q4 2025 was 67.09% at Outlook Therapeutics, down from 161.76% in the prior quarter.
  • The five-year high for Return on Sales was 161.76% in Q3 2025, with the low at 67.09% in Q4 2025.